WCLC2023 Archives - Geneseeq Technology Inc. | A Precision Oncology Company /tag/wclc2023/ We see precision medicine as the future of cancer care. Let’s accelerate precision cancer care, together. Tue, 29 Aug 2023 14:53:22 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 /wp-content/uploads/2019/09/geneseeq-fav.png WCLC2023 Archives - Geneseeq Technology Inc. | A Precision Oncology Company /tag/wclc2023/ 32 32 GENESEEQ TO SHARE EIGHT COLLABORATED STUDIES AT WCLC 2023 /geneseeq-to-share-eight-collaborated-studies-at-wclc-2023/ /geneseeq-to-share-eight-collaborated-studies-at-wclc-2023/#respond Tue, 29 Aug 2023 14:53:22 +0000 /?p=87564 Geneseeq will share three mini-oral presentations and five poster studies at the World Conference on Lung Cancer (WCLC) 2023, which […]

The post GENESEEQ TO SHARE EIGHT COLLABORATED STUDIES AT WCLC 2023 appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.

]]> Geneseeq will share three mini-oral presentations and five poster studies at the World Conference on Lung Cancer (WCLC) 2023, which will be held on September 9-12th, 2023 in Singapore. These Geneseeq-collaborated studies cover novel prognostic and predictive biomarkers in lung cancer, molecular characterization of prognosis-related lung cancer subtypes, and multi-omics analysis of lung cancer genomic and transcriptomic features.

ID Title
MA12.05 The Patterns & Prognostic Value of Clonal Seeding in Lung Cancer Metastasis
MA14.10 Spatiotemporal Heterogeneity of Genomic and Transcriptomic Landscape of Multiple Lung Cancer by a Novel Multi-omics Algorithm
MA18.05 Biomarkers for Brain Metastases Risk and Survival Benefit of Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer
P1.10-01 Enrichment of FA/HR aberrations in ATM/ATR-mutated NSCLC was accompanied by distinct molecular features and poor prognosis
P1.21-17 DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer
P1.22-09 Molecular Profiling Reveals Distinct Clinical and Genomic Features as Potential Therapeutic Targets in Pulmonary Spindle Cell Carcinoma
P1.23-09 Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study
EP12.01-49 Molecular Characteristics and Response to TKIs in NSCLC Patients with EGFR Exon 19 Insertions

The post GENESEEQ TO SHARE EIGHT COLLABORATED STUDIES AT WCLC 2023 appeared first on Geneseeq Technology Inc. | A Precision Oncology Company.

]]> /geneseeq-to-share-eight-collaborated-studies-at-wclc-2023/feed/ 0